Improving Treatments for Childhood Rhabdomyosarcoma
Targeting mTORC1 translational control in FOXO1 fusion positive rhabdomyosarcoma
This research looks for new ways to stop a type of childhood cancer called rhabdomyosarcoma from growing and becoming resistant to current medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11126020 on NIH RePORTER |
What this research studies
We are exploring how a specific type of childhood cancer, rhabdomyosarcoma with a FOXO1 gene fusion, relies on a process called mTORC1 for its growth. While new medicines that block mTORC1 show promise in initial tests, the cancer can sometimes return. Our goal is to understand why these cancers become resistant and find better ways to combine treatments to achieve lasting cures. We hope to provide information that helps doctors use these new medicines more effectively for children with this challenging cancer.
Who could benefit from this research
Good fit: This research is relevant for children, specifically those aged 0-11 years, who have rhabdomyosarcoma with a FOXO1 gene fusion.
Not a fit: Patients with other types of cancer or rhabdomyosarcoma without the FOXO1 gene fusion may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and lasting treatments for children with a difficult-to-treat form of rhabdomyosarcoma, potentially improving cure rates.
How similar studies have performed: New mTORC1 inhibitors are currently in early clinical testing and have shown strong results in laboratory models, but resistance remains a challenge that this work aims to address.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Sabnis, Amit J. — University of California, San Francisco
- Study coordinator: Sabnis, Amit J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.